BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11923219)

  • 1. A novel secreted splice variant of vascular endothelial cell growth inhibitor.
    Chew LJ; Pan H; Yu J; Tian S; Huang WQ; Zhang JY; Pang S; Li LY
    FASEB J; 2002 May; 16(7):742-4. PubMed ID: 11923219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis.
    Metheny-Barlow LJ; Li LY
    Semin Ophthalmol; 2006; 21(1):49-58. PubMed ID: 16517446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth.
    Hou W; Medynski D; Wu S; Lin X; Li LY
    Clin Cancer Res; 2005 Aug; 11(15):5595-602. PubMed ID: 16061878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
    Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
    Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.
    Zhai Y; Ni J; Jiang GW; Lu J; Xing L; Lincoln C; Carter KC; Janat F; Kozak D; Xu S; Rojas L; Aggarwal BB; Ruben S; Li LY; Gentz R; Yu GL
    FASEB J; 1999 Jan; 13(1):181-9. PubMed ID: 9872942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of N-terminal deletion on biological activity of vascular endothelial cell growth inhibitor].
    Zhang M; Wang L; Wang HW; Pan X; Pan W; Qi ZT
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Feb; 35(2):133-7. PubMed ID: 12545219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.
    Xiao T; Fan JK; Huang HL; Gu JF; Li LY; Liu XY
    Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of corneal neovascularization by vascular endothelial growth inhibitor gene].
    Wang B; Wang CF; Wang LH; Pang Q
    Zhonghua Yan Ke Za Zhi; 2008 Oct; 44(10):929-33. PubMed ID: 19176123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
    Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
    Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells.
    Bandyopadhyay A; Zhu Y; Malik SN; Kreisberg J; Brattain MG; Sprague EA; Luo J; López-Casillas F; Sun LZ
    Oncogene; 2002 May; 21(22):3541-51. PubMed ID: 12032856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
    Bates DO; Cui TG; Doughty JM; Winkler M; Sugiono M; Shields JD; Peat D; Gillatt D; Harper SJ
    Cancer Res; 2002 Jul; 62(14):4123-31. PubMed ID: 12124351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor.
    Yu J; Tian S; Metheny-Barlow L; Chew LJ; Hayes AJ; Pan H; Yu GL; Li LY
    Circ Res; 2001 Dec; 89(12):1161-7. PubMed ID: 11739281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo.
    Zhang HT; Scott PA; Morbidelli L; Peak S; Moore J; Turley H; Harris AL; Ziche M; Bicknell R
    Br J Cancer; 2000 Jul; 83(1):63-8. PubMed ID: 10883669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily.
    Zhai Y; Yu J; Iruela-Arispe L; Huang WQ; Wang Z; Hayes AJ; Lu J; Jiang G; Rojas L; Lippman ME; Ni J; Yu GL; Li LY
    Int J Cancer; 1999 Jul; 82(1):131-6. PubMed ID: 10360832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decorin suppresses tumor cell-mediated angiogenesis.
    Grant DS; Yenisey C; Rose RW; Tootell M; Santra M; Iozzo RV
    Oncogene; 2002 Jul; 21(31):4765-77. PubMed ID: 12101415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro.
    Zhang N; Sanders AJ; Ye L; Kynaston HG; Jiang WG
    Anticancer Res; 2010 Jan; 30(1):87-95. PubMed ID: 20150621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.